↓ Skip to main content

Cochrane Database of Systematic Reviews

Aripiprazole for schizophrenia

Overview of attention for article published in Cochrane database of systematic reviews, April 2006
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

blogs
1 blog
twitter
10 tweeters
weibo
1 weibo user

Citations

dimensions_citation
91 Dimensions

Readers on

mendeley
114 Mendeley
Title
Aripiprazole for schizophrenia
Published in
Cochrane database of systematic reviews, April 2006
DOI 10.1002/14651858.cd004578.pub3
Pubmed ID
Authors

Hany George El-Sayeh, Carla Morganti

Abstract

Treatment of people with schizophrenia using older typical antipsychotic drugs such as haloperidol can be problematic. Many fail to respond to these older antipsychotics and more people experience disabling adverse effects. Aripiprazole is said to be one of a new generation of atypical antipsychotics with good antipsychotic properties and minimal adverse effects.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 114 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 2 2%
United States 1 <1%
Spain 1 <1%
Norway 1 <1%
Unknown 109 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 23 20%
Student > Bachelor 18 16%
Student > Ph. D. Student 12 11%
Student > Doctoral Student 11 10%
Researcher 11 10%
Other 23 20%
Unknown 16 14%
Readers by discipline Count As %
Medicine and Dentistry 49 43%
Psychology 13 11%
Nursing and Health Professions 8 7%
Pharmacology, Toxicology and Pharmaceutical Science 6 5%
Neuroscience 5 4%
Other 16 14%
Unknown 17 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 April 2021.
All research outputs
#1,416,291
of 19,069,422 outputs
Outputs from Cochrane database of systematic reviews
#3,473
of 11,929 outputs
Outputs of similar age
#12,681
of 168,532 outputs
Outputs of similar age from Cochrane database of systematic reviews
#24
of 106 outputs
Altmetric has tracked 19,069,422 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,929 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 27.0. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,532 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 106 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.